Cargando…
CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
Melanoma remains a critical public health problem worldwide. Patients with stage IV disease have very poor prognosis and their 1-year survival rate is only 25%. Until recently, systemic treatments with a positive impact on overall survival (OS) had remained elusive. In recent years, the United State...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BlackWell Publishing Ltd
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430259/ https://www.ncbi.nlm.nih.gov/pubmed/25619164 http://dx.doi.org/10.1002/cam4.371 |